1. Home
  2. PPG vs RPRX Comparison

PPG vs RPRX Comparison

Compare PPG & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PPG Industries Inc.

PPG

PPG Industries Inc.

HOLD

Current Price

$111.18

Market Cap

23.1B

ML Signal

HOLD

Logo Royalty Pharma plc

RPRX

Royalty Pharma plc

HOLD

Current Price

$49.48

Market Cap

19.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PPG
RPRX
Founded
1883
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Paints/Coatings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.1B
19.5B
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
PPG
RPRX
Price
$111.18
$49.48
Analyst Decision
Buy
Strong Buy
Analyst Count
12
5
Target Price
$124.25
$51.40
AVG Volume (30 Days)
1.8M
2.5M
Earning Date
04-28-2026
05-06-2026
Dividend Yield
2.56%
1.90%
EPS Growth
46.11
N/A
EPS
6.94
1.78
Revenue
N/A
$2,378,193,000.00
Revenue This Year
$4.42
$38.63
Revenue Next Year
$3.03
$4.73
P/E Ratio
$15.98
$27.80
Revenue Growth
N/A
5.06
52 Week Low
$93.39
$31.58
52 Week High
$133.43
$50.08

Technical Indicators

Market Signals
Indicator
PPG
RPRX
Relative Strength Index (RSI) 53.57 63.62
Support Level $102.00 $35.32
Resistance Level $114.98 N/A
Average True Range (ATR) 2.89 0.91
MACD 0.87 0.08
Stochastic Oscillator 61.44 84.32

Price Performance

Historical Comparison
PPG
RPRX

About PPG PPG Industries Inc.

PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: